A228760 Stock Overview
A biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Genomictree Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩21,700.00 |
| 52 Week High | ₩30,950.00 |
| 52 Week Low | ₩13,090.00 |
| Beta | -0.029 |
| 11 Month Change | 7.16% |
| 3 Month Change | -6.47% |
| 1 Year Change | 45.64% |
| 33 Year Change | 52.28% |
| 5 Year Change | 15.43% |
| Change since IPO | 382.22% |
Recent News & Updates
Shareholder Returns
| A228760 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -10.9% | -0.09% | -0.05% |
| 1Y | 45.6% | 20.1% | 6.0% |
Return vs Industry: A228760 exceeded the KR Biotechs industry which returned 20.1% over the past year.
Return vs Market: A228760 exceeded the KR Market which returned 6% over the past year.
Price Volatility
| A228760 volatility | |
|---|---|
| A228760 Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A228760 has not had significant price volatility in the past 3 months.
Volatility Over Time: A228760's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 81 | Sung-Whan An | www.genomictree.com |
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraTect-KRAS and AccuraTect-BRAF that are companion diagnostics for colorectal cancer; AccuraTect-EGFR, a companion diagnostic for lung cancer; and AccuraDTect SARS-CoV-2 RT-qPCR kits, as well as test providers.
Genomictree Inc. Fundamentals Summary
| A228760 fundamental statistics | |
|---|---|
| Market cap | ₩520.41b |
| Earnings (TTM) | -₩8.24b |
| Revenue (TTM) | ₩2.54b |
205.1x
P/S Ratio-63.1x
P/E RatioIs A228760 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A228760 income statement (TTM) | |
|---|---|
| Revenue | ₩2.54b |
| Cost of Revenue | ₩3.53b |
| Gross Profit | -₩993.01m |
| Other Expenses | ₩7.25b |
| Earnings | -₩8.24b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -343.66 |
| Gross Margin | -39.14% |
| Net Profit Margin | -324.82% |
| Debt/Equity Ratio | 1.4% |
How did A228760 perform over the long term?
See historical performance and comparison